USYMRO 130mg concentrate for solution for infusion medication leaflet

L04AC05 • ustekinumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Ustekinumab is a human monoclonal antibody used to treat autoimmune inflammatory diseases such as moderate-to-severe plaque psoriasis, psoriatic arthritis, and inflammatory bowel diseases like Crohn's disease and ulcerative colitis. It works by blocking interleukins IL-12 and IL-23, cytokines involved in inflammatory and autoimmune processes.

By inhibiting these cytokines, ustekinumab reduces inflammation and symptoms associated with these conditions, such as skin lesions, joint pain, diarrhea, and abdominal pain. It is administered as a subcutaneous injection or intravenous infusion, depending on the indication, according to a schedule determined by a healthcare provider.

Common side effects include upper respiratory tract infections, headaches, fatigue, and injection site reactions. Rarely, severe infections, allergic reactions, or an increased risk of certain cancers may occur.

Patients should inform their doctor about any other medical conditions or medications before starting ustekinumab. Regular monitoring is essential to assess the treatment's effectiveness and safety.